Drugs / Camostat
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04782505 | Mar 2021 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1/23 trials · 2 missed | ||||||
| Phase 1/2 | NCT04435015 | Nov → Dec 2021 | COVID-19, blood coagulation disease | Yale University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04321096 | Apr 2020 → Jan 2022 | COVID-19 | University of Aarhus | Completed | Missed primary |
| Phase 1/2 | NCT02693093 | Feb 2016 → Sep 2021 | chronic pancreatitis | Kangen Pharmaceuticals, Inc | Completed | Missed primary |
| Phase 213 trials · 4 missed | ||||||
| Phase 2 | NCT06794593 | Nov 2024 → Dec 2025 overdue | chronic kidney disease | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05474664 | Oct 2022 → Jul 2024 | Fontan-associated liver disease, protein-losing enteropathy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04662086 | Apr 2021 → May 2022 | COVID-19 | Stanford University | Completed | Missed primary |
| Phase 2 | NCT04662073 | Apr → Jun 2021 | COVID-19 | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04681430 | Jan → Oct 2021 | COVID-19 | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 2 | NCT04524663 | Dec 2020 → May 2021 | COVID-19 | Stanford University | Completed | Missed primary |
| Phase 2 | NCT04583592 | Nov 2020 → Mar 2021 | COVID-19 | Sagent Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 2 | NCT04625114 | Nov 2020 → Jul 2022 | COVID-19 | University Hospital, Ghent | Terminated | No outcome recorded |
| Phase 2 | NCT04455815 | Sep 2020 → Nov 2021 | COVID-19 | Cancer Research UK | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04470544 | Jul 2020 → Dec 2021 | severe acute respiratory syndrome | Alan Bryce | Completed | No outcome recorded |
| Phase 2 | NCT04353284 | Jun 2020 → Mar 2021 | COVID-19 | Yale University | Completed | Missed primary |
| Phase 2 | NCT04374019 | May → Dec 2020 | COVID-19 | Susanne Arnold | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00506792 | Jul 2007 → Dec 2008 | cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT04730206 | Jun 2021 → Jul 2022 | COVID-19 | KU Leuven | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04608266 | Dec 2020 → Sep 2021 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Terminated | Missed primary |
| Phase 3 | NCT04355052 | Apr → Oct 2020 | COVID-19 | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04338906 | May 2020 → Dec 2021 | COVID-19 | Heinrich-Heine University, Duesseldorf | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT04652765 Comparator | Feb → Sep 2021 | COVID-19 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04750759 Comparator | Feb → Oct 2021 | COVID-19 | Charité Research Organisation GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT04530617 Comparator | Oct 2020 → Jun 2021 | COVID-19, diabetes mellitus, hypertensive disorder, obesity disorder | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-11 | Ono Pharmaceutical Co., Ltd. | Results Phase III Study Result of FOIPAN® Tablets, a Protease Enzyme Inhibitor, in Japan in Patients with Novel Coronavirus Infection (COVID-19) ono-pharma.com ↗
Based on the result, ONO conducted a Phase III study with Foipan in patients with asymptomatic to moderate COVID-19, but did not show the efficacy of Foipan in the study. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-11 | Ono Pharmaceutical Co., Ltd. | Phase III Study Result of FOIPAN® Tablets, a Protease Enzyme Inhibitor, in Japan in Patients with Novel Coronavirus Infection (COVID-19) ono-pharma.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camostat | “We conducted a clinical trial to further investigate the efficacy and safety of camostat, an oral serine protease inhibitor that has been used to alleviate pain in CP.” PMID 38103842 ↗ Dec 202311“Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.” PMID 23412700 ↗ Jul 2013 “Camostat 600mg by mouth four times a day, for a total of 7 days” NCT04652765 ↗ “Camostat mesylate Tablet from Daewoong” NCT04782505 ↗ |
| Known as | Camostat mesilate | “NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity and has been widely used for the treatment of...” PMID 31412955 ↗ Aug 201911“Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);” NCT04625114 ↗ “Camostat mesilate” NCT04455815 ↗ |
| Known as | camostat mesylate | “Therefore, the CLOCC trial will evaluate the efficacy and safety of a combination therapy consisting of hydroxychloroquine, which was used already as single agent with some...” NCT04338906 ↗7“Treatment was 7 days of oral camostat mesylate, 200 mg po four times a day, or placebo.” PMID 35132421 ↗ Jan 2022 “Camostat mesylate” NCT04455815 ↗ |
| Known as | Foipan | “a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo” NCT04338906 ↗2“Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);” NCT04625114 ↗ “camostat mesylate (Foipan®)” NCT04681430 ↗ |
| Known as | NI-03 | “NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity and has been widely used for the treatment of...” PMID 31412955 ↗ Aug 2019 |
| Action | Inhibit | “Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF).” PMID 23412700 ↗ Jul 2013 |
| Route | Intranasal | “camostat administered through a nasal spray pump” PMID 23412700 ↗ Jul 2013 |
| Target | TMPRSS2 | “TMPRSS2 inhibitor camostat mesilate” PMID 33903855 ↗ Apr 2021 |